PB Fintech extends losses, falls another 5%; key concall takeaways, how insurance stocks are faring

After showing signs of recovery in early trade, shares of insurance-linked stocks once again slipped into the red on Friday, September 25, extending their losses from Thursday’s session.

PB Fintech shares gained as much as 4.5% to hit a high of ₹1,261.70 on the NSE, a day after the stock nosedived 36% — its worst single-day fall on record.

However, the stock reversed its early gains and was trading at ₹1,140 on the NSE, down 5.56% at 10:44 AM.

Insurance-linked stocks witnessed heavy selling pressure on Thursday, with insurance distributors PB Fintech and Turtlemint Fintech among the worst hit, after the Insurance Regulatory and Development Authority of India (IRDAI) proposed changes to the commission structure and regulations governing insurance distributors.

The proposed changes have raised concerns over their potential impact on distributor revenues and the broader insurance distribution ecosystem, triggering a sharp sell-off across insurance and financial stocks.

What PB Fintech said in analyst call

However, the company said it would wait for greater regulatory clarity on the proposal before taking any decision.

PB Fintech said lower distribution commissions could alter the economics of its existing business model and make insurance manufacturing a more relevant strategic option.

Under the commission framework proposed by the Insurance Regulatory and Development Authority of India (IRDAI), there would be product-level commission caps.

In general insurance, the proposed first-year commission on individual health policies is 15%, compared with the prevailing commission of around 30% for distribution entities and 20% for agents.

Renewal and portability commissions are proposed to be capped at 5% and 10%, respectively. PB Fintech termed the IRDAI proposals “quite extreme”.

The company’s management said a distributor with a large customer base could have an advantage if it eventually entered insurance manufacturing, as it would already have access to a sizeable distribution network. However, PB Fintech said the economics would need to work for both the company and its partners.

What is insurance manufacturing?

Insurance manufacturing refers to the business of creating and underwriting insurance products, rather than simply selling policies offered by other insurers.

In simple terms, an insurance manufacturer is the company that designs the policy, decides the terms and pricing, assesses and takes on the insurance risk, and pays claims when covered events occur.

This is different from an insurance distributor or broker, which mainly connects customers with insurance companies and earns commissions for selling their policies.

How other insurance-linked stocks are faring

Turtlemint Fintech Solutions was trading nearly 17% lower at ₹90.79 on the NSE. The stock had crashed 20% on Thursday.

Among insurance companies, HDFC Life Insurance Company was down 1.6% at ₹518.45 on the NSE, while SBI Life Insurance was trading over 1% lower at ₹1,736. Max Financial Services was up 1% at ₹1,423.90, while ICICI Prudential Life Insurance was down 1% at ₹460.15 on the NSE.

ICICI Lombard General Insurance was trading 0.48% lower at ₹1,569.40 on the NSE.

What leading analysts said on PB Fintech

BofA

BofA said the proposed distribution framework could make insurance distribution unattractive for larger agents and is directionally negative for the online insurance broking industry.

It expects the impact on Policybazaar’s life and term insurance business to remain manageable, while the company’s capital allocation is likely to stay focused on protecting its core position.

BofA also lowered the valuation multiple for PB Fintech’s core business. However, it believes Policybazaar could gain market share across insurance categories. The investment firm said the risk of asymmetric commission cuts — a key investor concern — is now behind the company.

It also noted that Policybazaar could explore manufacturing health insurance, while higher investments by PB Health in the hospital business could help build a stronger competitive edge.

Jefferies

Jefferies expects the proposed framework to have a larger impact on the company’s non-life insurance business than on life insurance. It estimates that a 10% cut in new-business commission rates could translate into a 10–12% decline in earnings.

Jefferies expects PB Fintech to focus on cost optimisation in the near term. However, it noted that the proposed changes are still at the consultation stage and could undergo modifications after feedback from stakeholders.

Morgan Stanley

Morgan Stanley flagged a potentially significant impact on PB Fintech’s health insurance business, estimating that its NPV could decline 60–70% under the proposed framework, while the life insurance NPV is expected to remain broadly stable. The investment firm said the company is evaluating opportunities in insurance manufacturing, reinsurance broking and new products.

Morgan Stanley also noted that PB Fintech is seeking an Managing General Agents (MGA) regulatory framework that could reward quality distributors. It expects lower insurance premiums to potentially support demand growth.

The company does not plan any knee-jerk layoffs and sees scope for cost savings, while risks remain to the top line of PB Partners’ POSP business.

It also expects PB Fintech to focus on reducing losses at Paisabazaar and its UAE operations.

HSBC

HSBC said the proposed distribution reforms, including commission caps for insurers, could have a material impact on PB Fintech.

HSBC has cut its FY28 and FY29 earnings estimates by 56% and 17%, respectively, as the impact of lower take rates is expected to be partly offset by slightly higher growth and cost savings.

It said regulatory clarity will remain a key catalyst for the stock.